

## Assessing the Safety of Stem Cell Therapeutics

Chris E.P. Goldring,\* Paul A. Duffy, Nissim Benvenisty,\* Peter W. Andrews, Uri Ben-David, Rowena Eakins, Neil French, Neil A. Hanley, Lorna Kelly, Neil R. Kitteringham,\* Jens Kurth, Deborah Ladenheim, Hugh Lavery, James McBlane, Gopalan Narayanan, Sara Patel, Jens Reinhardt, Annamaria Rossi, Michaela Sharpe, and B. Kevin Park

\*Correspondence: [c.e.p.goldring@liverpool.ac.uk](mailto:c.e.p.goldring@liverpool.ac.uk) (C.E.P.G.), [nissimb@cc.huji.ac.il](mailto:nissimb@cc.huji.ac.il) (N.B.), [neilk@liv.ac.uk](mailto:neilk@liv.ac.uk) (N.R.K.)

DOI [10.1016/j.stem.2011.06.006](https://doi.org/10.1016/j.stem.2011.06.006)

(Cell Stem Cell 8, 619–629; June 3, 2011)

The title and discussion associated with Table 1 misrepresented the ongoing trials listed as being based solely on pluripotent stem cells, when in fact some are based on other cell types. It also omitted one trial being carried out by Osiris Therapeutics. The table included in the online version of the article and the corresponding text have been amended to correct these misrepresentations. We apologize for any confusion caused.